Roivant Sciences Ltd (ROIV)
Roivant Sciences Ltd. (ROIV) Presents at Leerink Global Healthcare Conference 2026 Transcript
Roivant Sciences Ltd. (ROIV) Presents at Leerink Global Healthcare Conference 2026 Transcript
Roivant Sciences Ltd. (ROIV) Discusses $2.25 Billion Global Settlement Resolving COVID Vaccine Patent Litigation Transcript
Roivant Sciences Ltd. (ROIV) Discusses $2.25 Billion Global Settlement Resolving COVID Vaccine Patent Litigation Transcript
Roivant Sciences Ltd. (ROIV) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Roivant Sciences Ltd. (ROIV) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Roivant: The Next Telavant Has Arrived With Brepocitinib's Blockbuster Data (Rating Upgrade)
Roivant: The Next Telavant Has Arrived With Brepocitinib's Blockbuster Data (Rating Upgrade)
Roivant Sciences Ltd. (ROIV) Q3 2025 Earnings Call Transcript
Roivant Sciences Ltd. (ROIV) Q3 2025 Earnings Call Transcript
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.27.
Roivant Sciences Ltd. (ROIV) Presents at 44th Annual J.P.
Roivant Sciences Ltd. (ROIV) Presents at 44th Annual J.P.
Roivant Sciences Ltd. (ROIV) Q2 2025 Earnings Call Transcript
Roivant Sciences Ltd. (ROIV) Q2 2025 Earnings Call Transcript
Roivant Sciences Ltd. (ROIV) Presents at Jefferies London Healthcare Conference 2025 Transcript
Roivant Sciences Ltd. ( ROIV ) Jefferies London Healthcare Conference 2025 November 18, 2025 12:00 PM EST Company Participants Matthew Gline - CEO & Director Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Presentation Yuchen Ding Jefferies LLC, Research Division Good afternoon.
Roivant Sciences: Brepocitinib And Roadmap Still Underpriced
ROIV's holding-company model with its Vants continues creating shareholder value. They then recycle M&A and partnership proceeds into late-stage assets. ROIV focuses on autoimmune and rare-disease drug programs. Recent promising Phase 3 data for DM with Brepocitinib have helped the stock appreciate. Brepocitinib could tap into a sizeable TAM over time, and its NDA filing for DM is expected by 1H2026. Plus, it can target NIU and CS.
Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Lags Revenue Estimates
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.27.
Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2025 Transcript
Roivant Sciences Ltd. (NASDAQ:ROIV ) Bank of America Global Healthcare Conference 2025 September 24, 2025 5:45 AM EDT Company Participants Matthew Gline - CEO & Director Conference Call Participants Jason Gerberry - BofA Securities, Research Division Presentation Jason Gerberry BofA Securities, Research Division We're at time.
